Buyout buzz hits fever pitch on report that Nektar is ‘exploring options’
The buzz about a possible acquisition of Nektar Therapeutics $NKTR has been intense over the last few weeks, especially as new M&A deals have begun to pour through. So maybe it’s not a huge surprise to hear that Bloomberg is reporting Friday afternoon that the biotech is exploring its options, and perhaps a sale.
Nektar spotlighted NKTR-214 at SITC last fall, raising interest for a therapy that hopes to make waves in I/O.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.